Time to onset analysis of letrozole associated osteonecrosis of jaw in FDA adverse event reporting system (FAERS) database

被引：0
|
作者：
Viswam, Subeesh Kulangara [1 ]
Reddy, Neha [1 ]
Gouri, Nair [1 ]
Sai, Minnikanti Satya [1 ]
Kunnavil, Radhika [2 ]
Maheswari, Eswaran [1 ]
机构：
[1] MS Ramaiah Univ Appl Sci, Bangalore, Karnataka, India
[2] Ramaiah Med Coll, Bangalore, Karnataka, India
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2020年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
2328
引用
收藏
页码：460 / 460
页数：1
相关论文
共 50 条
  • [1] Osteonecrosis of the Jaw Associated With Bevacizumab in Treatment: A Case Series Using the FDA Adverse Event Reporting System (FAERS) Database
    Ahdi, Hardeep S.
    Wichelmann, Thomas A.
    Pandravada, Sasirekha
    Ehrenpreis, Eli
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S119 - S119
  • [2] Time to onset analysis of montelukast associated suicidal ideation using data from FDA adverse event reporting system database (FAERS)
    Viswam, Subeesh Kulangara
    Reddy, Neha
    Yalamanchili, Jahnavi
    Dsouza, Prizvan Lawrence
    Mazhar, Faizan
    Gouri, Nair
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 479 - 479
  • [3] Pharmacovigilance analysis of orlistat adverse events based on the FDA adverse event reporting system (FAERS) database
    Zhu, Jinfeng
    Hu, Mianda
    Liang, Yingshi
    Zhong, Mingjun
    Chen, Zilin
    Wang, Zhenjie
    Yang, Yujia
    Luo, Ziyi
    Zeng, Wenqi
    Li, Jiahui
    Du, Yikuan
    Liu, Yi
    Yang, Chun
    [J]. HELIYON, 2024, 10 (14)
  • [4] A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
    Shu-peng Zou
    Hai-yun Yang
    Meng-ling Ouyang
    Qian Cheng
    Xuan Shi
    Ming-hui Sun
    [J]. BMC Pharmacology and Toxicology, 24
  • [5] Pantoprazole associated dyspepsia hypocalcemia and hyponatremia: A disproportionality analysis in FDA adverse event reporting system (FAERS) database
    Nair, Harsha Prakash
    Kulkarni, Apoorva Rachana
    Eswaran, Maheswari
    Subeesh, Viswam
    [J]. ARAB JOURNAL OF GASTROENTEROLOGY, 2023, 24 (01) : 1 - 4
  • [6] A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
    Zou, Shu-peng
    Yang, Hai-yun
    Ouyang, Meng-ling
    Cheng, Qian
    Shi, Xuan
    Sun, Ming-hui
    [J]. BMC PHARMACOLOGY & TOXICOLOGY, 2023, 24 (01):
  • [7] Adverse events associated with brolucizumab: a disproportionality analysis of the FDA adverse event reporting system (FAERS)
    Xiong, Xiaomei
    Zhang, Xiuwen
    Li, Xiaoxia
    Huang, Taomin
    [J]. EXPERT OPINION ON DRUG SAFETY, 2024,
  • [8] Drug Repurposing Using FDA Adverse Event Reporting System (FAERS) Database
    Morris, Robert
    Ali, Rahinatu
    Cheng, Feng
    [J]. CURRENT DRUG TARGETS, 2024, 25 (07) : 454 - 464
  • [9] Pharmacovigilance of triazole antifungal agents: Analysis of the FDA adverse event reporting system (FAERS) database
    Zhou, Jianxing
    Wei, Zipeng
    Xu, Baohua
    Liu, Maobai
    Xu, Ruichao
    Wu, Xuemei
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [10] A disproportionality analysis of sunitinib in the FDA adverse event reporting system (FAERS)
    Zou, Wenbin
    Yang, Han
    Xi, Yu
    Zeng, Chenxi
    Chen, Wei
    Fu, Xiangning
    [J]. HELIYON, 2024, 10 (17)
12345